Jiangsu Yahong Licenses CEVIRA® to Theramex, Expanding Global Cervical Precancer Reach
Jiangsu Yahong Meditech’s exclusive licensing of Theramex’s cervical‑precancer drug CEVIRA® expands its global reach and opens a high‑margin revenue stream amid a stable healthcare fund.
3 minutes to read